bioMérieux – 2018 Financial Results
27 February, 2019
- Organic sales growth of 9.9% for full-year 2018:
- €2,421 million in sales
- Up 5.8% as reported
- Solid fourth-quarter performance, with organic growth of more than 10%
- Improvement in...
You are here
bioMérieux acquires Invisible Sentinel, a US-based company specialized in food and beverage molecular testing
07 February, 2019
bioMérieux, a global player in in vitro diagnostics and world leader in food microbiology testing, today announced the acquisition of Invisible Sentinel Inc. This company, based in Philadelphia (PA) develops, manufactures and markets innovative and...
bioMérieux receives FDA clearance for BPA and BPN culture bottles used with BACT/ALERT® VIRTUO® for quality control testing of platelets
19 December, 2018
bioMérieux, a world leader in the field of in vitro diagnostics, announces that its culture bottles BACT/ALERT® BPA and BPN have received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for quality control testing of leukocyte-...
bioMérieux launches the BIOFIRE® FILMARRAY® Pneumonia Panels with FDA clearance and CE Marking
13 November, 2018
bioMérieux, a world leader in the field of in vitro diagnostics, today announced the Food and Drug Administration (FDA) 510(k) clearance of the BIOFIRE® FILMARRAY® Pneumonia Panel and the CE-Mark of the BIOFIRE® FILMARRAY®...
bioMérieux acquires a majority stake in Hybiome and strengthens its presence both in China and in the immunoassay market
09 November, 2018
bioMérieux, a world leader in the field of in vitro diagnostics, today announces the acquisition of a majority holding in Suzhou Hybiome Biomedical Engineering Co.Ltd. This announcement follows the acquisition of a minority stake in July 2018.
Founded in...
Business review for the nine months ended September 30, 2018
18 October, 2018
- Strong sales dynamic confirmed in third quarter, with an 8.8% increase in organic sales
- Growth of 9.8% at constant exchange rates and scope of consolidation over the nine months ended September 30:
- €1,749 million in sales
- Up 4.5% as reported
bioMérieux commitments in the CDC’s “AMR Challenge”, a joint public-private sector initiative to accelerate the fight against antimicrobial resistance
25 September, 2018
Marcy l’Étoile (France) – Sept. 25, 2018 – bioMérieux, a world leader in the field of in vitro diagnostics, is participating in the AMR Challenge, a new Centers for...
First-Half 2018 Results
05 September, 2018
- Strong sales dynamic, with sales up 10.4% over the first half at constant exchange rates and scope of consolidation:
- €1,169 million in sales
- Up 3.1% as reported
- Contributive operating income before non-...
Second-Quarter 2018 Business Review
18 July, 2018
- Strong sales dynamic confirmed in second quarter, leading to sales up 10.4% over the first half at constant exchange rates and scope of consolidation:
- €1,169 million in sales
- Up 3.1% as reported
- ...
NEPHROCHECK® Biomarkers TIMP-2 and IGFBP7 Included in Acute Dialysis Quality Initiative Recommendations
12 June, 2018
The biomarkers in the NEPHROCHECK® test, an FDA-cleared and CE-marked urine test that indicates kidney stress in advance of acute kidney injury...